{
    "id": 24061,
    "fullName": "FANCC loss",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "FANCC loss indicates loss of the FANCC gene, mRNA, and protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2176,
        "geneSymbol": "FANCC",
        "terms": [
            "FANCC",
            "FA3",
            "FAC",
            "FACC"
        ]
    },
    "variant": "loss",
    "createDate": "07/06/2016",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7220,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived FANCC-deficient head and neck squamous cell carcinoma cells demonstrated sensitivity to PJ-34 in cell culture (PMID: 25609062).",
            "molecularProfile": {
                "id": 24787,
                "profileName": "FANCC loss"
            },
            "therapy": {
                "id": 2541,
                "therapyName": "PJ34",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6219,
                    "pubMedId": 25609062,
                    "title": "Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25609062"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7219,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient-derived FANCC-deficient head and neck squamous cell carcinoma cells demonstrated sensitivity to Lynparza (olaparib) in cell culture (PMID: 25609062).",
            "molecularProfile": {
                "id": 24787,
                "profileName": "FANCC loss"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6219,
                    "pubMedId": 25609062,
                    "title": "Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25609062"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 24787,
            "profileName": "FANCC loss",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}